BioCentury
ARTICLE | Financial News

CRISPR Therapeutics adds $38M to series B round

June 25, 2016 12:22 AM UTC

Gene editing company CRISPR Therapeutics AG (Basel, Switzerland) raised $38 million in the final close of its series B round, bringing the round's total to about $140 million. Participating were new institutional investors and specialized healthcare funds including Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners and Wellington Capital Management.

In April 2015, CRISPR Therapeutics raised $29 million for the round's first close. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) invested $30 million as part of a four-year research collaboration, and Bayer AG (Xetra:BAYN) added $35 million as part of a deal to create a JV focused on blood disorders, blindness and congenital heart disease. Both deals were announced in 4Q15 (see BioCentury, Jan. 4). ...